Ken Griffin Voyager Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.77 - $9.27 $39,813 - $63,963	-6,900 Reduced 55.2%	5,600 $32,000
Q2 2024 Aug 14, 2024	BUY	$7.42 - $10.54 $12,614 - $17,918	1,700 Added 15.74%	12,500 $98,000
Q1 2024 May 15, 2024	BUY	$7.15 - $10.84 $36,465 - $55,284	5,100 Added 89.47%	10,800 $100,000
Q4 2023 Feb 14, 2024	SELL	$6.28 - $8.81 $4,396 - $6,167	-700 Reduced 10.94%	5,700 $48,000
Q3 2023 Nov 14, 2023	SELL	$7.55 - $11.25 $71,725 - $106,875	-9,500 Reduced 59.75%	6,400 $49,000
Q2 2023 Aug 14, 2023	SELL	$6.94 - $13.99 $2,082 - $4,197	-300 Reduced 1.85%	15,900 $182,000
Q1 2023 May 15, 2023	SELL	$6.0 - $10.78 $8,400 - $15,092	-1,400 Reduced 7.95%	16,200 $124,000
Q4 2022 Feb 14, 2023	SELL	$4.94 - $6.61 $120,042 - $160,623	-24,300 Reduced 58.0%	17,600 $107,000
Q3 2022 Nov 14, 2022	SELL	$5.57 - $7.47 $26,736 - $35,856	-4,800 Reduced 10.28%	41,900 $248,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.